donanemab
antibody · Eli Lilly · APOE as stratifier
Current state
- Status
- Approved — 2 active of 6 tracked studies
- Sponsor
- Eli Lilly
- Modality
- antibody
- Mechanism
- anti-amyloid, APOE4-stratified ARIA risk
- Thesis
- APOE as stratifier
- Record checked
- Verified by a curator
- Last change
- (2 days ago)
- Last reviewed
- (2 days ago)
Trials — 6
| NCT | Title | Phase | Status | Start | Primary completion | N | APOE-strat. |
|---|---|---|---|---|---|---|---|
| NCT03367403 | — | unknown | — | — | — | no | |
| NCT05026866 | — | unknown | — | — | — | no | |
| NCT05108922 | A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) | PHASE3 | COMPLETED | 148 | no | ||
| NCT06911944 | Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation | PHASE4 | NOT_YET_RECRUITING | 60 | no | ||
| NCT06996730 | A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease | PHASE2/PHASE3 | NOT_YET_RECRUITING | 240 | no | ||
| NCT07602582 | — | unknown | — | — | — | no |
Publications — 0
No linked publication. Nothing has been resolved to this therapeutic in Europe PMC or OpenAlex. Where nobody has checked the record yet, this usually means the identifier is used inconsistently in the literature rather than that no work exists.
Change history — 2
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
new study registeredNCT06996730Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
new study registeredNCT06911944
No changes match the current filter. 0 high, 2 medium and 0 low-significance changes are in this snapshot — re-enable a level above to see them.